SecBot SecBot
8-K ·Filed Jul 9, 2026

ANVS

Annovis Bio, Inc.
NEUTRAL
Impact 6/10
Horizonmonths Processed4mo ago SEC0001104659-26-082341
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Trial enrollment completion reduces operational risk but shifts the focus to binary efficacy readouts. The stock will likely trade on sentiment and cash runway until Q1 2027 symptomatic data. Monitor for any equity or debt financing updates given the early-stage biotech capital needs through 2028.

DirectionNeutral
Confidencehigh
Horizonmonths

buntanetap

● Neutral Named in this 8-K
Impact
Phase
Phase 3
Time to market
If Phase 3 Alzheimer's succeeds, NDA submission could come in early 2027 (symptomatic) or early 2028 (disease-modifying). Earliest potential FDA approval would be late 2028 at best.
Next catalyst
None dated

What to watchInvestors should watch for the Q1 2027 Alzheimer's Phase 3 symptomatic readout as the defining catalyst. The company will likely need additional financing before then given ~$14M cash and ~$17M/quarter burn. The Parkinson's miss on ITT primary endpoint is a cautionary precedent. Analyst consensus is strong-buy with $11 mean PT, but that reflects binary-option-like upside rather than de-risked fundamentals.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.86
T+0 close · Jul 9, 2026 · via day close
Latest settled
−35.48%
T+60 · $1.20
Vs SPY
−38.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 10 $1.86entry
  2. T+1 · 4mo ago −5.38%α −4.61% · $1.76
  3. T+5 · 4mo ago −6.45%α −5.89% · $1.74
  4. T+20 · 3mo ago +1.08%α −1.35% · $1.88
  5. T+60 · 6w ago −35.48%α −38.12% · $1.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Annovis Bio announced full enrollment of its pivotal Phase 3 trial (NCT06709014) of buntanetap for early Alzheimer's disease, enrolling 850 patients across 83 US sites, exceeding original projections. The dual-readout trial provides symptomatic data in Q1 2027 and disease-modifying data in Q1 2028, with NDA submissions targeted after each readout. This is an operational milestone that de-risks trial execution but provides no efficacy data, leaving the binary outcome intact.

Key Facts

  • Full enrollment of 850 patients in pivotal Phase 3 trial of buntanetap for early Alzheimer's disease, exceeding original projections
  • Trial conducted across 83 clinical sites in the US with pTau217-confirmed AD pathology
  • 6-month symptomatic top-line data readout expected Q1 2027
  • 18-month disease-modifying top-line data readout expected Q1 2028
  • Company preparing for two separate NDA submissions following each respective data readout
  • In Q2 2025 (one year prior), the trial had only 50 patients enrolled

Financial Impact

No financial data provided in the filing

Risk Factors

  • Phase 3 efficacy/safety failure of buntanetap would be a binary negative event
  • Cash burn risk given timeline to Q1 2028 disease-modifying readout (no revenue disclosed)
  • Regulatory risk, FDA may require additional data beyond the two planned readouts

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-082341
Document: tm2620172d1_ex99-1.htm0001104659-26-082341
Document: 0001104659-26-082341-index-headers.html0001104659-26-082341
Document: 0001104659-26-082341-index.html0001104659-26-082341
Document: 0001104659-26-082341.txt0001104659-26-082341

US Market Status

Market Closed · Opens in 5h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 10, 2026